Osteoclast lineage commitment and differentiation have been studied extensively, although the mechanism by which transcription factor(s) control osteoclast terminal differentiation, activation, and function remains unclear. CCAAT/enhancer-binding protein  (C/ebp) has been reported to be a key regulator of osteoclast cell lineage commitment, yet C/ebp's roles in osteoclast terminal differentiation, activation and function, and bone homeostasis, under physiological or pathological conditions, have not been studied because newborn C/ebp-null mice die within several hours after birth. Furthermore, the function of C/ebp in osteoclast terminal differentiation, activation, and function is largely unknown. Herein, we generated and analyzed an osteoclast-specific C/ebp conditional knockout (CKO) mouse model via Ctsk-Cre mice and found that C/ebp-deficient mice exhibited a severe osteopetrosis phenotype due to impaired osteoclast terminal differentiation, activation, and function, including mildly reduced osteoclast number, impaired osteoclast polarization, actin formation, and bone resorption, which demonstrated the novel function of C/ebp in cell function and terminal differentiation. Interestingly, C/ebp deficiency did not affect bone formation or monocyte/macrophage development. Our results further demonstrated that C/ebp deficiency suppressed the expression of osteoclast functional genes, e.g. encoding cathepsin K (Ctsk), Atp6i (Tcirg1), and osteoclast regulator genes, e.g. encoding c-fos (Fos), and nuclear factor of activated T-cells 1 (Nfatc1), while having no effect on Pu.1 (Spi1) expression. Promoter activity mapping and ChIP assay defined the critical cis-regulatory element (CCRE) in the promoter region of Nfatc1, and also showed that the CCREs were directly associated with C/ebp, which enhanced the promoter's activity. The deficiency of C/ebp in osteoclasts completely blocked ovariectomy-induced bone loss, indicating that C/ebp is a promising new target for the treatment of osteolytic diseases.
Introduction
Osteoclasts (OCs) are multinucleated cells of hematopoietic origin that play indispensable roles in skeletal development, bone remodeling, and bone homeostasis. Excessive osteoclastic activity from defective osteoclastogenesis and impaired osteoclast function leads to many metabolic bone diseases (e.g. osteoporosis, arthritis, and periodontal diseases). Osteoclasts originate from monocytic precursors of the hematopoietic cell lineage upon stimulation with the macrophage-colony stimulation factor (M-CSF) and receptor activator of nuclear factor-κB (RANK) ligand (RANKL) [1] . Despite the fact that some transcription factors which regulate osteoclast lineage commitment and differentiation have been characterized [the Finkel-Biskis-Jinkins osteosarcoma oncogene (c-fos; Fos), proviral integration 1 (Pu.1; Spi1), nuclear factor-kappa B (NF-κB; Nfkb1), and nuclear factor of activated T-cells 1 (Nfatc1; Nfatc1)], the mechanism underlying transcription factor regulation of osteoclast terminal differentiation, maturation, and function remains unclear [2] .
CCAAT/enhancer binding protein α (C/ebpα) dimer272 W Chen et al myeloid leukemia (AML) often involve abrogation of C/ebpα expression and/or function [5] . The peripheral blood of mice lacking C/ebpα has significantly fewer granulocytes and monocytes [3] , indicating that C/ebpα plays important roles in monocyte lineage specification. We have recently identified C/ebpα as the CCRE binding protein at a proximal region of the promoter of Ctsk, encoding osteoclast-specific cathepsin K [6] , and that C/ebpα is essential for osteoclast lineage commitment [6, 7] . Although C/ebpα is a well-established lineage regulatory determinant in early hematopoietic development [5, 8, 9] , several studies have also suggested that it has multiple functions in several cell types [10] [11] [12] [13] . The roles of C/ebpα in postnatal skeletal development and bone homeostasis have not been studied as newborn C/ebpα-null mice die within several hours after birth [4] . Additionally, the mechanisms underlying the roles of C/ebpα in postnatal physiological and pathological skeletal development remain elusive.
In this study, we generated a novel osteoclast-specific C/ebpα deletion mouse model to examine C/ebpα's roles in osteoclast activation and function, as well as to characterize the regulatory roles of C/ebpα in the terminal differentiation stages of cells of hematopoietic origin. We discovered that C/ebpα controls osteoclast terminal differentiation, activation, function, and postnatal bone homeostasis. Further, we found that C/ebpα directly regulates Nfatc1 expression and defined the CCREs in the promoter regions of Nfatc1, and that conditional knockout of C/ebpα completely protected mice against ovariectomy-induced bone loss.
Materials and methods
More details are provided in Supplementary materials and methods. For primer sequences and Taqman probes, please refer to Tables S1 and S2.
Ethics
All animal experimentation was carried out according to the legal requirements of the Association for Assessment and Accreditation of Laboratory Animal Care International and the University of Alabama at Birmingham Institutional Animal Care and Use Committee.
Generation of C/ebpα
f/f Ctsk-Cre mice C/ebpα f/f mice [9, 14] were crossed with Ctsk-Cre knock-in mice. Male C/ebpα F/+Ctsk-Cre and female C/ebpα F/+Ctsk-Cre mice were crossed to obtain C/ebpα f/f Ctsk-Cre and C/ebpα f/f mice. The investigators were not blinded during allocation, animal handling, and endpoint measurements. Genotyping by PCR was carried out as previously described [15] .
Histomorphometric analysis
Samples were non-decalcified hard-tissue sections processed as described previously [16, 17] . Analysis of sections was performed using the NIH program ImageJ as described previously [18] .
Mouse bone marrow (MBM) and osteoclast-like cells
MBM was obtained as previously described [19, 20] . MBM was cultured in α-MEM (Invitrogen, Carlsbad, CA, USA) with 10% FBS (Invitrogen) containing M-CSF (20 ng/ml). After 1 day, cells were further cultured in the presence of 10 ng/ml soluble RANKL (Peprotech, Rocky Hill, NJ, USA) and M-CSF (10 ng/ml; R&D Systems, Minneapolis, MN, USA).
Cell staining for F-actin rings F-actin ring formation was evaluated as previously depicted [21] . Microscopy and 3D construction were performed as previously described [22] .
Acridine orange staining
Acid production was determined using acridine orange as described previously [23] . The experiment was performed in duplicate on four independent occasions in a 12-or 6-well plate.
Promoter analyses
The mouse Nfatc1 promoter was amplified using PCR from BAC clones provided by the BACPAC Resource Center at Children's Hospital Oakland Research Institute. Luciferase activity was measured as previously described [6, 17] .
Ovariectomy (OVX) procedure

C/ebpα
f/f/Δ and C/ebpα f/f mice were dorsal ovariectomized or sham-operated upon under anesthesia as previously described [24] . At 3 months post-operation, femurs and uteri were harvested for phenotypic and radiological analysis as previously described [25] .
Statistical analysis
Experimental data are reported as mean ± SEM or mean ± SD of triplicate independent samples with both male and female mice in each group. Data were analyzed using Student's t-test or two-way ANOVA using the statistical program GraphPad Prism (GraphPad Software, Inc, La Jolla, CA, USA). P values less than 0.05 were considered significant. Error bars depict SEM or SD as mentioned in individual figure legends.
Results
C/ebpα
f/f Ctsk-Cre mice display an osteopetrotic phenotype that becomes accentuated as mice age C/ebp is essential for bone homeostasis 273 function in vivo. We therefore generated the CKO model, C/ebpα f/f Ctsk-Cre, using osteoclast-specific Ctsk-Cre-mediated targeted disruption of C/ebpα to further characterize C/ebpα's role in osteoclast homeostasis. Compared with wild-type mice, heterozygous Ctsk-Cre and C/ebpα f/f mice had no detectable bone phenotype; C/ebpα f/f mice hence served as the control group in this study (supplementary material, Figure S1B ). During the early stages of skeletal development (1 week), male and female C/ebpα f/f Ctsk-Cre mice exhibited an increase in bone radiodensity, indicating osteopetrosis ( Figure 1A ). Bone radiographs were also examined at various time points in adult and aged mice (12 and 22 weeks); the existing osteopetrotic condition became progressively worse in older C/ebpα-deficient mice compared with their WT littermates ( Figure 1B, C) . Further analysis and quantification of C/ebpα f/f Ctsk-Cre and C/ebpα f/f mouse cortical bone showed no significant difference between the periosteum circumference of 12-and 22-week-old C/ebpα f/f Ctsk-Cre and C/ebpα f/f mice but a significant decrease in the endosteum circumference in the C/ebpα f/f Ctsk-Cre mice compared with the C/ebpα f/f mice (supplementary material, Figure  S1C ). Analysis of mouse cranial development in 2, 4, 8, and 12-week-old mice showed no overt effects of CKO on tooth eruption or skull phenotype ( Figure 1D ). When compared with that in C/ebpα f/f mice, the serum concentration of carboxy-terminal collagen crosslinks (CTX; bone resorption marker) had decreased by nearly two-fold and, surprisingly, by almost four-fold in 12-and 22-week-old C/ebpα f/f Ctsk-Cre mice, respectively ( Figure 1E ). Micro-computed tomography (μ-CT) analysis of the distal femora of 12-week-old female C/ebpα f/f Ctsk-Cre mice revealed that femurs from mutant mice had increased trabecular numbers and higher ratios of bone volume/tissue volume compared with those of C/ebpα f/f mice ( Figure 1F , H). Interestingly, while 12-week-old C/ebpα f/f Ctsk-Cre mice showed only a mild osteopetrotic phenotype ( Figure 1F , H), older C/ebpα f/f Ctsk-Cre mice (22 weeks old) experienced a much more severe osteopetrotic condition that was marked by a significant increase in bone density ( Figure 1G, I ). Our data suggest that Ctsk-Cre-mediated CKO of C/ebpα results in osteopetrosis that was accentuated as the mice aged.
Impaired osteoclast polarization and function contribute to the osteopetrotic phenotype displayed by C/ebpα f/f Ctsk-Cre mice to detect the differences in bone formation showed no significant changes in bone formation between mutant and WT femurs ( Figure 2D , E), confirming that the reduced bone density was not caused by decreased bone formation. Consistently, H&E staining and Goldner's trichrome staining indicated a significant increase in mineralized tissue in 22-week-old C/ebpα f/f Ctsk-Cre mice ( Figure 2F , G). Higher-magnification images showed that mutant mice lacked the gaps between osteoclasts and trabecular bones (i.e. Howship's lacunae), due to reduced osteoclastic bone resorption ( Figure 2G ). Histomorphometric measurements based on trichrome staining also confirmed that the severity of osteopetrosis persisted and increased over the course of bone development without affecting osteoblast number in C/ebpα f/f Ctsk-Cre mice at 22 weeks of age ( Figure 2H ). Since osteoclasts differentiate from cells of hematopoietic origin, we sought to assess the status of monocyte/macrophage development in C/ebpα f/f Ctsk-Cre mice. Flow cytometry was performed using 8-week-old mouse bone marrow (MBM) to examine the infiltration of CD11b + F4/80 + macrophages ( Figure 2I ) and CD11b
Although the number of macrophages in mutant mice remained similar to that in WT, the number of osteoclasts in CKO mice was significantly reduced ( Figure 2K ). Consistently, the P1NP serum level (bone formation marker) remained unaltered between C/ebpα f/f Ctsk-Cre and C/ebpα f/f , indicating that the bone formation rate in both long and flat bones was not affected by C/ebpα CKO ( Figure 2L ). These results show that osteoclast lineage-specific C/ebpα deletion impairs osteoclast terminal differentiation, which results in reduced osteoclastic bone resorption, leading to a higher bone density in vivo.
C/ebpα deficiency impairs the activation and function of multinucleated osteoclasts in vitro
In order to determine whether C/ebpα excision has an effect on mature osteoclast function and structure, MBM from 6-week-old C/ebpα f/f Ctsk-Cre and WT mice was stimulated by M-CSF (10 ng/ml) and RANKL (10 ng/ml) to promote the formation of mature MNCs (defined as TRAP-positive cells with three or more visible nuclei). We then performed extensive in vitro osteoclast differentiation and functional assays using RANKL/M-CSF-induced C/ebpα f/f Ctsk-Cre MBM at the end of a 5-day osteoclastogenic culture. Although reduced TRAP activity was evident in CKO, MNC formation was still possible in C/ebpα-deficient mice ( Figure 3A , D), further confirming a mild defect in osteoclast formation. In osteoclast functional assay, we found that extracellular acidification was almost absent ( Figure 3B , E) and that actin formation was defective ( Figure 3C their inactive status ( Figure 3F, G) . We further examined the molecular distribution of Ctsk by performing immunofluorescence staining of the induced osteoclast cells on bone slices. Ctsk expression in mature, multinucleated osteoclasts obtained from WT culture was indeed co-localized with osteoclast ruffled borders. Ctsk expression in osteoclasts depleted of C/ebpα showed an approximate seven-fold reduction ( Figure 3H ), and actin ring formation on the bone slice of the C/ebpα-deficient OCs was inhibited ( Figure 3I ). Thus, it is possible that C/ebpα plays a critical role in regulating Ctsk expression, thereby resulting in its critical role in osteoclast function. Furthermore, wheat germ agglutinin (WGA) staining and scanning electron microscopy (SEM) analysis conclusively confirmed defective osteoclastic bone resorption resulting from targeted disruption of C/ebpα ( Figure 3J, K) , in which bone resorption pits were significantly reduced compared with the C/ebpα f/f control ( Figure 3L ). Collectively, these data indicate that C/ebpα CKO impairs cell activation and function in osteoclast terminal differentiation, and that C/ebpα is essential for in vitro bone resorption of osteoclasts.
Ctsk-Cre-mediated targeted disruption of C/ebpα significantly reduces the expression of osteoclast regulator and functional genes in osteoclasts Figure S2B , C). c-fos and Nfatc1 expression was evidently suppressed; however, Pu.1 remained almost unchanged compared with the control samples (supplementary material, Figure  S2D -F). We also found no significant changes in the numbers of F4/80-positive macrophages between WT and mice lacking C/ebpα (supplementary material, Figure S2G , H). Taken together, our results demonstrated that Ctsk-Cre-mediated CKO of C/ebpα caused C/ebpα deficiency that inhibited the expression of osteoclast function and regulator genes at the protein level, and that C/ebpα deficiency no longer affects Pu.1 expression during the later stages of osteoclast development.
C/ebpα CKO in C/ebpα
f/f Ctsk-Cre does not affect apoptosis in osteoclasts during the early stages of cytokine and serum deprivation 278 W Chen et al by Hoechst 33258 staining followed by staining of F-actin podosomal belts with rhodamine phalloidin of the induced osteoclasts. Although the positive control exhibited apoptosis with typical fragmentation, aggregation, and condensation (white arrows) of nuclei (supplementary material, Figure S3A ), the apoptotic parameters were mostly similar in the WT and mutant cells (supplementary material, Figure  S3B , C). Extensive apoptosis culture also showed that C/ebpα-deficient mature osteoclasts did not survive longer than WT cells during the first 12 h of the apoptotic test, whereas more C/ebpα f/f Ctsk-Cre osteoclasts underwent apoptosis at 24 h (supplementary material, Figure S3D ).
C/ebpα positively regulates the expression of osteoclast transcriptional regulators and osteoclast function genes
To investigate the molecular mechanism underlying the role of C/ebpα in bone homeostasis, we examined the expression of the aforementioned osteoclast functional genes along with important osteoclast regulator genes in C/ebpα f/f Ctsk-Cre mice ( Figure 5A, B) . Deletion of C/ebpα was confirmed by western blot and qPCR analysis ( Figure 5A, B) . Quantitative protein analysis showed that deficiency of C/ebpα significantly reduced the expression of key osteoclast transcription factors (e.g. c-fos, Nfatc1) as well as important osteoclast function effectors (e.g. Ctsk, ATP6i) in CKO mice compared with the controls (i.e. C/ebpα f/f and Ctsk-Cre) ( Figure 5A and supplementary material, Figure S4) . Notably, Pu.1 expression remained unaltered in C/ebpα f/f Ctsk-Cre mice compared with that of control groups ( Figure 5A and supplementary material, Figure S4 ). At the transcript level, RT-qPCR analysis displayed a similar pattern in which deficiency of C/ebpα downregulated the levels of Ctsk, ATP6i, c-fos, Nfatc1, and other critical osteoclast-specific genes, yet the Pu.1 levels remained unchanged ( Figure 5B ). Together, our results indicate that C/ebpα is a crucial regulator of osteoclast terminal differentiation, activation, and function through positively regulating osteoclast transcription regulators and osteoclast function genes.
C/ebpα directly upregulates Nfatc1 expression by associating with its promoters
Since we have previously identified potential binding sites for C/ebpα in the c-fos promoter, we used a ChIP assay to further determine the binding patterns between C/ebpα and the Nfatc1 (−2990/+10) promoter regions using DNA prepared from MBM induced by RANKL and M-CSF for 4 days as previously described [26, 27] . ChIP analysis was performed using an anti-C/ebpα antibody. DNA was pulled down, amplified, and analyzed using the primers shown in Figure 5C . The ChIP input value using each primer represents the binding efficiency of an adjacent region around the location of the primer pair. We found several C/ebpα binding sites in the Nfatc1 promoter region (−2990/+10), and we also found that Nfatc1 primer pair 2 (−1832/−1771) and primer pair 3 (−1353/−1237) in the Nfatc1 promoter region (−2990/+10) resulted in significantly high ChIP input values, indicating that C/ebpα binding sites at −1852, −1740, −1375, and −1281 in the Nfatc1 promoter region are the most efficient ( Figure 5D ). Macrophage-like RAW264.7 cells were induced by RANKL and M-CSF for 2 days to promote the formation of multinucleated osteoclasts and then transfected with the corresponding luciferase reporter vectors. Luciferase assay showed the highest activity in the longest Nfatc1 promoter fragment (−2768/+10) which gradually decreased in shorter fragments; however, the −1345/+10 promoter fragment still retained significantly higher luciferase activity compared with the pGL3-basic vector control ( Figure 5E ). Thus, C/ebpα is able to directly bind to the Nfatc1 promoter to regulate gene expression, and the binding sites −1852, −1740, −1374, and −1281 are critical in this interaction.
C/ebpα
f/f Ctsk-Cre mice exhibit protection against ovariectomy-induced bone loss Figure 6H ). At the same time, no significant changes were found between sham and OVX-C/ebpα f/f Ctsk-Cre mice ( Figure 6I ). These findings suggest that C/ebpα deficiency in C/ebpα f/f Ctsk-Cre mice protected mice from OVX-induced bone loss, which provides significant insights into the roles of C/ebpα in regulating bone density in normal and OVX conditions. C/ebpα may be a promising novel approach for the treatment of osteolytic diseases. 
C/ebpα deficiency does not affect mouse body weight
To further determine whether C/ebpα CKO caused runt phenotype in mutant mice, we examined the mouse body weights of C/ebpα f/f and C/ebpα f/f Ctsk-Cre mice ( Figure 6I, J) . In the pathologically induced model, there was no change in mouse body weight across OVX and sham groups of mutant and wild-type mice ( Figure 6J ). In the physiological aging process, both male and female C/ebpα f/f and C/ebpα f/f Ctsk-Cre mice exhibited similar size and body weight at various stages of skeletal development ( Figure 6K and supplementary material, Figure S6A ).
Forced expression of C/ebpα in the absence of RANKL promotes osteoclastogenesis and upregulates the expression of osteoclast-specific genes
We used a retrovirus to express C/ebpα ectopically in MBM cells with only M-CSF (20 ng/ml) stimulation. The retrovirus vector, pBMN-C/ebpα, was engineered to express C/ebpα and also GFP in order to measure transduction efficiency. MBM cells were transduced with pBMN-C/ebpα or a control virus (pBMN-GFP) as previously described [28] . C/ebpα expression in MBM transfected with pBMN-C/ebpα became significantly higher than that in the control vector at 48 h and continuously increased throughout the remaining time points (supplementary material, Figure S5A , B). At 96 h after M-CSF induction, GFP-positive cells were visualized to measure transduction efficacy (supplementary material, Figure S5C ). We also found that bone marrow with C/ebpα overexpression developed a significantly higher number of TRAP + cells (supplementary material, Figure S5D ). The sensitivity of C/ebpα-overexpressing bone marrow in the absence of RANKL establishes the importance of C/ebpα in promoting TRAP + cells. RT-qPCR revealed a significant increase in c-fos, Nfatc1, Ctsk, and Mmp9 levels, while Pu.1 levels remained unchanged in pBMN-GFP-transfected MBM compared with wild-type and control vector (supplementary material, Figure S5E ). TRAP activity was significantly enhanced in C/ebpα-overexpressing MBM cells seeded on bone slices compared with pBMN-GFP controls, indicating their activated bone resorption capability (supplementary material, Figure  S5F ). RANKL-independent osteoclast formation can be driven by IL-6 and TNF. Interestingly, C/ebpα overexpression significantly upregulated the expression of Il6, but not Tnf , pinpointing a possible mechanism underlying the RANKL-independent C/ebpα-mediated regulation of osteoclast homeostasis (supplementary material, material, Figure S6 ). Taken together, these results indicate a critical stimulatory role of C/ebpα in osteoclast terminal differentiation, activation, and function.
Discussion
C/ebpα is an important transcriptional regulator of hematopoiesis, which acts through its ability to bind DNA and influence the transcriptional activities of different genes. Recent studies have exclusively argued for the importance of C/ebpα in monocyte/macrophage and OC lineage allocation [8, 29] . In this study, we found that in vivo osteoclast terminal differentiation in C/ebpα CKO mice was affected along with severely impaired osteoclastic bone resorption, which suggests that C/ebpα might play a critical, yet independent, role in osteoclast terminal differentiation. C/ebpα can be removed from the cell through a ubiquitin-proteasome system-mediated mechanism [30] ; hence RANKL may protect C/ebpα from being degraded, thereby leading to its high expression in the cytoplasm during osteoclastogenic induction. C/ebpα up-regulates Nfatc1 expression through directly binding to a CCRE in the promoter region of Nfatc1, which then directly binds to osteoclast gene promoters to drive their expression. C/ebpα's effects on osteoclast terminal differentiation may also be enhanced by the direct interaction betweenhigh level of Ctsk mRNA in dendritic cells ( Figure S6) . Notably, we recently discovered an important osteoimmune role that Ctsk plays in regulating the cytokine secretion in LPS and CpG-stimulated dendritic cells [31] . Hence, it is possible that besides its direct activity in inducing the expression of important osteoclast regulator and function genes in osteoclasts, C/ebpα may indirectly affect osteoclast function through altering Ctsk expression in other tissues, specifically in dendritic cells, thereby mediating secretions of pro-inflammatory cytokines to activate RANKL-independent bone formation. Although our research previously showed that constitutive C/ebpα ablation significantly reduced Pu.1 expression and that C/ebpα could play major roles in osteoclast lineage commitment [6] , Pu.1 expression in C/ebpα f/f Ctsk-Cre mice remained unchanged (Figures 4 and 5) , indicating that C/ebpα no longer regulates Pu.1 expression in pre-osteoclast and osteoclast stages as cell lineage determination has already taken place. It had been shown that some differentiation status-related epigenetic changes associated with the Pu.1 promoter region have the potential to repress Pu.1 transcriptional activity. In contrast, c-fos (a key regulator of osteoclast-macrophage lineage determination) is significantly downregulated in C/ebpα f/f Ctsk-Cre mice, suggesting an important role for c-fos throughout osteoclast development, possibly due to direct interactions with the C/ebpα binding sites in the promoter region of the c-fos gene [6] . C/ebpα may also directly up-regulate osteoclast function genes (e.g. Ctsk and Atp6i), leading to the increase in expression of key osteoclast function genes, which can mediate osteoclastic bone resorption involving actin ring formation, extracellular acidification, and matrix protein degradation.
C/ebpα deficiency in osteoclasts completely protected mice against OVX-induced bone loss; thus, C/ebpα inhibitors may lead to desirable therapeutics and further optimize the current treatment options for local bone loss in periodontal disease. However, screening for effective C/ebpα inhibitors can be problematic in systemic osteolytic disorders, as C/ebpα is ubiquitously expressed and involved in proliferation arrest and the differentiation of multiple cell types. To overcome these limitations and further our current understanding of osteoclast biology, it is important to explore the mechanisms underlying how C/ebpα specifically regulates osteoclast activation and function, and to reveal effective upstream C/ebpα regulators that are specific to osteoclasts. Given its differential roles in different stages of cell development, understanding how C/ebpα regulates osteoclast terminal differentiation, activation, and function also provides important mechanistic insights into osteoclast biology knowledge that can greatly benefit future research in the investigation of potential C/ebpα regulators, significant pathways in the pathogenesis of acute myeloid leukemia, as well as pointing to a new target for the development of future novel and effective treatments for osteolytic diseases. 
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